MTOR and diffuse lymphatic malformation: Accordingly, sirolimus, an inhibitor of mammalian target of rapamycin (mTOR), a kinase in the PI3K/AKT/mTOR pathway, appears effective at stabilizing signs/symptoms of disease in patients with GLA with mutations in this pathway (149, 150).